The Artificial Pancreas: Current Situation and Future Directions presents research on the top issues relating to the artificial pancreas (AP) and its application to diabetes. AP is a newer form of treatment to accurately and efficiently inject insulin, thereby significantly improving the patient's quality of life. By connecting a continuous glucose monitor (CGM) to a continuous subcutaneous insulin infusion using a control algorithm, AP delivers and regulates the most accurate amount of insulin to maintain normal glycemic values. Featured chapters in this book are written by world leaders in AP research, thus providing readers with the latest studies and results.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Feedback control algorithms for automated glucose management in T1DM: the state of the art 2. Getting IoT-ready 3. Multivariable AP with adaptive control 4. The ARG algorithm: clinical trials in Argentina 5. Use of intraperitoneal insulin delivery for artificial pancreas 6. Physiological models for artificial pancreas development 7. Deployment of modular MPC for type 1 diabetes control: the Italian experience 2008-2016 8. Integrating the clinical and engineering aspects of closed-loop control: the Virginia experience 9. Strategies to mitigate hypoglycaemia in the artificial pancreas 10. Multiple-signal artificial pancreas systems 11. Artificial pancreas in pediatrics
Authors
Ricardo S. Sánchez-Peña Director of the Research and Ph.D. Program, Buenos Aires Institute of Technology (ITBA), CABA, Argentina.
Ricardo S. Sánchez-Peña received the Electronic Engineer degree from the University of Buenos Aires (UBA, 1978) and the M.Sc. and Ph.D. from the California Institute of Technology (1986, 1988), both in Electrical Engineering. In Argentina, he worked since 1977 in different research institutions. He collaborated with NASA, the German (DLR) and Brazilian (CTA/INPE) space agencies. He was (Plenary) Full Professor at UBA (1989-2004), ICREA Senior Researcher at the UPC (2005-2009, Barcelona) and visiting Prof./Researcher at several Universities in the USA and EU. He consulted for companies in the USA, Spain, and Argentina. He published four books and more than 160 journal and conference papers. He received awards from NASA, IEEE, and the National Academy of Exact, Physical, and Natural Sciences of Argentina. He is Director of the Research and Ph.D. Program at the Buenos Aires Institute of Technology (ITBA) and Investigador Superior from CONICET. He has applied identification and control to acoustical, mechanical, aero, and astronautical engineering and currently to type 1 diabetes and neurobiology.
Daniel R. Cherñavvsky Assistant Professor of Research, Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
Daniel R. Cherñavvsky is Assistant Professor of Research in the Center for Diabetes Technology at the University of Virginia. The Center for Diabetes Technology is a multidisciplinary group of research academicians with specialties in Pediatrics, Endocrinology, Behavioral Medicine, Systems Engineering, Mathematics, and Statistics, working collaboratively for the advancement of technology for the treatment of type 1 diabetes. Currently, Dr. Cherñavvsky is leading several artificial pancreas studies in pediatric and young adult populations. In addition, Dr. Cherñavvsky collaborates with the International Artificial Pancreas (iAP) Study Group, which joins investigators from Italy, France, Israel, Argentina, and the USA. He had conducted the first-ever outpatient clinical study of a cell phone-based artificial pancreas system and performed US and international outpatients-based trials with different generations of the Artificial Pancreas system. Dr. Cherñavvsky's funded studies include summer and winter camps with adolescents evaluating the effect of exercise and type 1 diabetes. Dr. Cherñavvsky, a pediatric nephrologist and pediatric intensive care specialist graduate from the University of Buenos Aires, has conducted and designed clinical research projects for over 15 years in the USA. Since September 2016, he joined TypeZero Technologies, Inc., as a part time chief medical officer. Now he divides his time between academia, continuing his clinical research activities, and industry, where he is moving forward technological products aiming to optimize treatment for people with type 1 diabetes.
